- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Kalveer Flora, MPharm: Biosimilar Savings and the NHS
Kalveer Flora, MPharm, London North West University Healthcare National Health Service (NHS) Trust, discusses how biosimilar savings have been put to use by the NHS.
Transcript
As we know, the [National Health Service, NHS] is always in the news as being cash-strapped. The demand is so high, whereas the resources we have are so low. So if we know that we can save money by using a drug that’s just as efficacious and works just as well as a more expensive drug, it’s so beneficial for the NHS to use a more cost-effective drug.
This has been seen through using etanercept, rituximab, and adalimumab biosimilars. The NHS has been able to save a pot of money which they can use for more expensive treatments with cancer. We know now that, in the UK, [National Institute for Health and Care Excellence, NICE], which is a regulator that approves medicines for us, has now approved CAR-T therapy, which is a new drug therapy which is very expensive, and we’ve only been able to do that through biosimilar savings.
So it’s using savings from biosimilars to use in cancer, multiple sclerosis, migraine treatments, and that’s the way forward now.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
